Key result
Depression in heart failure patients is associated with a twofold increase in mortality compared to those without depression, and pharmacological management has not improved major outcomes.
Why the study?
Does pharmacological management or psychotherapy improve outcomes in patients with heart failure and depression?
Does pharmacological management or psychotherapy improve outcomes in patients with heart failure and depression?
Depression is highly prevalent in heart failure and doubles mortality risk, yet pharmacological treatments have not demonstrated improved major clinical outcomes.
Answers are grounded in this paper and cite their sources.
May warrant depression screening in HF care; leaves open optimal interventions.
Depression is a major issue in heart failure (HF). Depression is present in about one in five HF patients, with about 48 % of these individuals having significant depression. There is a wide variation in reported prevalences because of differences in the cohorts studied and methodologies. There are shared pathophysiological mechanisms between HF and depression. The adverse effects of depression on the outcomes in HF include reduced quality of life, reduced healthcare use, rehospitalisation and increased mortality. Results from metaanalysis suggest a twofold increase in mortality in HF patients with compared to those without depression. Pharmacological management of depression in HF has not been shown to improve major outcomes. No demonstrable benefits over cognitive behavioural therapy and psychotherapy have been demonstrated.
No takes yet. Share an insight, caveat, or question.
Mbakwem et al. (2016) conducted a review in Heart failure. Depression vs. No depression was evaluated on Mortality (twofold increase). Depression in heart failure patients is associated with a twofold increase in mortality compared to those without depression, and pharmacological management has not improved major outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: